IP International Journal of Comprehensive and Advanced Pharmacology
Official Publication of Khyati Education And Research Foundation
Official Publication of Khyati Education And Research Foundation
Print ISSN:-2581-5555
Online ISSN:-2456-9542
CODEN : IIJCDU
Review Article
Author Details :
Volume : 7, Issue : 3, Year : 2022
Article Page : 115-122
https://doi.org/10.18231/j.ijcaap.2022.024
Abstract
Paliperidone is a BCS-II drug. It means paliperidone is poorly water soluble and hence shows problem in absorption as well as permeation through GIT which together contributes for its lower oral bioavailability. Paliperidone as drug, oil oleic acid, surfactant labrasol and co surfactant labrafil m 1944 were taken and formulation were done. From the emulsification time study as the concentration of Smix increases emulsification time decreases. Further emulsification time study I found that F3 has the lowest emulsification time. From the dissolution study it was observed that Q30 is above 85% obtained for formulation F3 and F6 that is 93.75 & 91.25. This can be due to the higher concentration of Smix present in formulation F3 & F6 since mean cumulative % drug release at 30min (Q30) is highest for F3 formulation and it was selected for optimized formulation. As in the DSC study thecrystalline property of Paliperidone is lost and it becomes amorphous. In the FT-IR study there is no significance sifting of characteristic peak. Hence there is no incompatibility between drug and excipient.
Keywords: Paliperidone, Labrafil, Emulsification time, Formulation
How to cite : Lakshmi V, Sunitha N, Babu S M, Formulation, optimization and evaluation of self nanoemulsifying drug delivery system of paliperidone. IP Int J Compr Adv Pharmacol 2022;7(3):115-122
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
